{"id":"NCT01534208","sponsor":"Repros Therapeutics Inc.","briefTitle":"Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism","officialTitle":"An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2012-02-16","resultsPosted":"2014-07-24","lastUpdate":"2014-07-24"},"enrollment":499,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Secondary Hypogonadism"],"interventions":[{"type":"DRUG","name":"Androxal","otherNames":["Enclomiphene citrate"]}],"arms":[{"label":"Androxal 12.5 mg","type":"EXPERIMENTAL"},{"label":"Androxal 25 mg","type":"EXPERIMENTAL"}],"summary":"ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.","primaryOutcome":{"measure":"Change From Baseline in Total Morning Testosterone at 26 Weeks","timeFrame":"6 months","effectByArm":[{"arm":"Androxal 12.5 mg","deltaMin":280.9,"sd":141.4},{"arm":"Androxal 25 mg","deltaMin":214.7,"sd":154.7}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":207},"commonTop":["Upper respiratory tract infection","Headache","Muscle spasms","Sinusitis","Influenza"]}}